It is known that NLRP3 signaling drives resistance to anti-PD-1 immunotherapy and is responsible for adaptive immune suppression through promoting the production of IL-1β in pancreatic carcinoma [82]. Here, NLRP3 is linked to exocrine pancreatic carcinoma.